Related Experiment Videos
Stop-codon read-through for patients affected by a lysosomal storage disorder
Doug A Brooks1, Viv J Muller, John J Hopwood
1Lysosomal Diseases Research Unit, Department of Genetic Medicine, Children Youth and Women's Health Service, 72 King William Rd, North Adelaide, South Australia 5006, Australia. douglas.brooks@adelaide.edu.au
Trends in Molecular Medicine
|June 27, 2006
Summary
Enhanced stop-codon read-through therapy offers a promising new approach for lysosomal storage disorders. Gentamicin demonstrated potential in preclinical studies to restore enzyme activity and reduce substrate accumulation in affected cells.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Lysosomal storage disorders (LSDs) are inherited conditions causing progressive pathology due to lysosomal dysfunction.
- Current treatments like enzyme replacement and bone-marrow transplantation have limitations.
- Premature stop-codon mutations are found in a significant number of LSD patients.
Purpose of the Study:
- To explore enhanced stop-codon read-through as a therapeutic strategy for LSDs.
- To investigate the efficacy of gentamicin in inducing read-through of premature stop codons in LSD cells.
Main Methods:
- Utilized mucopolysaccharidosis type I (MPS I) cells deficient in alpha-L-iduronidase.
- Administered gentamicin to induce premature stop-codon read-through.
- Assessed resulting enzyme activity and substrate storage levels.
Main Results:
- Gentamicin successfully induced read-through of premature stop codons in MPS I cells.
- This read-through resulted in restored alpha-L-iduronidase enzyme activity.
- Reduced accumulation of stored substrates was observed in treated cells.
Conclusions:
- Enhanced stop-codon read-through, using agents like gentamicin, is a viable therapeutic strategy for LSDs with premature stop codons.
- This approach holds potential as an alternative or adjunct therapy to current treatments.
- Further research is warranted to translate these preclinical findings into clinical applications.